Skip to main content
. 2019 May 20;12:1577–1604. doi: 10.2147/JPR.S192174

Table 4.

Overall treatment-emergent adverse event (TEAE) experience

(n) (%)
Total population 800 (100)
Subjects with at least one TEAE 159 (19.9)
Subjects with ...1 TEAE 119 (14.9)
...2 TEAEs 33 (4.1)
..3 TEAEs 7 (0.9)
Nervous system disorders 52 (6.5)
Dysgeusia 23 (2.9)
Dizziness 10 (1.3)
Drowsiness 6 (0.8)
Somnolence 5 (0.6)
Headache 3 (0.4)
Memory impairment 3 (0.4)
Disturbance in attention 2 (0.3)
Gastrointestinal disorders 42 (5.3)
Nausea 10 (1.3)
Dry mouth 14 (1.8)
Mouth discomfort 9 (1.1)
Vomiting 6 (0.8)
Diarrhea 2 (0.3)
Oral pain 1 (0.1)
General disorders and administration site conditions 23 (2.9)
Feeling abnormal 9 (1.1)
Fatigue 8 (1.0)
Application site pain 6 (0.8)
Psychiatric disorders 16 (2.0)
Disorientation 6 (0.8)
Depressed mood 5 (0.6)
Confusion 4 (0.5)
Anxiety 1 (0.1)
Metabolism and nutrition disorders 56 (7.0)
Increased appetite 50 (6.3)
Anorexia 6 (0.8)
Respiratory, thoracic and mediastinal disorders 17 (2.1)
Pharyngolaryngeal pain 14 (1.8)
Dyspnoea 3 (0.4)
Total number of TEAEs 206 (100)
Metabolism and nutrition disorders 56 (27.2)
Nervous system disorders 52 (25.2)
Gastrointestinal disorders 42 (20.4)
General disorders and administration site conditions 23 (11.2)
Respiratory, thoracic and mediastinal disorders 17 (8.3)
Psychiatric disorders 16 (7.8)
TEAE intensity …mild 168 (81.6)
…moderate 34 (16.5)
…severe 4 (1.9)
TEAE-related treatment discontinuations (pats.) 32 (4.0)
Discontinuation due to …dysgeusia 14 (1.8)
…dizziness 6 (0.8)
…fatigue 6 (0.8)
…mouth discomfort 4 (0.5)
…somnolence 2 (0.3)
Efficacy-related treatment discontinuations (pats.) 113 (14.1)
Treatment discontinuations for any reasons (pats.) 145 (18.1)